Biogen, Eisai Submit Biologics License Application for Alzheimer's Subcutaneous Autoinjector to US FDA

MT Newswires Live11-01

Biogen (BIIB) and Eisai said late Thursday that Eisai finalized a biologics license application rolling submission to the FDA for a subcutaneous autoinjector of LEQEMBI, or lecanemab-irmb, for weekly dosing in early-stage Alzheimer's disease.

The device, which is designed for home or clinic use, allows a 15-second injection and supports sustained drug levels to clear toxic protofibrils linked to Alzheimer's disease progression.

Biogen is co-commercializing and co-promoting the product, while Eisai serves as the lead for lecanemab's development and regulatory submissions, the companies said.

Eisai said the FDA set the Prescription Drug User Fee Act, or PDUFA action date for January 25, 2025.

Price: 173.90, Change: -0.10, Percent Change: -0.06

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment